CN115023222A - 神经系统病症的治疗 - Google Patents

神经系统病症的治疗 Download PDF

Info

Publication number
CN115023222A
CN115023222A CN202080093141.6A CN202080093141A CN115023222A CN 115023222 A CN115023222 A CN 115023222A CN 202080093141 A CN202080093141 A CN 202080093141A CN 115023222 A CN115023222 A CN 115023222A
Authority
CN
China
Prior art keywords
methylumbelliferone
derivative
use according
salt
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080093141.6A
Other languages
English (en)
Chinese (zh)
Inventor
J·夸克
R·福斯特
J·邓肯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Leeds
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN115023222A publication Critical patent/CN115023222A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202080093141.6A 2019-10-25 2020-10-25 神经系统病症的治疗 Pending CN115023222A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962926001P 2019-10-25 2019-10-25
US62/926,001 2019-10-25
PCT/EP2020/079979 WO2021078991A1 (en) 2019-10-25 2020-10-25 Treatment of conditions of the nervous system

Publications (1)

Publication Number Publication Date
CN115023222A true CN115023222A (zh) 2022-09-06

Family

ID=73455660

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080093141.6A Pending CN115023222A (zh) 2019-10-25 2020-10-25 神经系统病症的治疗

Country Status (5)

Country Link
US (1) US20220380331A1 (https=)
EP (1) EP4048257A1 (https=)
JP (1) JP2022554230A (https=)
CN (1) CN115023222A (https=)
WO (1) WO2021078991A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023099818A1 (en) * 2021-11-30 2023-06-08 Evexys Biotech Oy Prevention and treatment of depressive disorders and conditions promoted by protease containing plasma extracellular vesicles (pcpev)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1929839A1 (de) * 1968-06-14 1969-12-18 Dausse Lab 4-tert.-Aminomethyl-7-hydroxycumarine
US6617124B1 (en) * 1998-05-08 2003-09-09 Smithkline Beecham P.L.C. 7-alkoxycoumarins as cytochrome p450 substrates
WO2006102958A1 (en) * 2005-03-29 2006-10-05 Newron Pharmaceuticals S.P.A. Substituted aminoalkyl- and amidoalkyl-benzopyran derivatives
CN103446154A (zh) * 2012-05-29 2013-12-18 中国医学科学院药物研究所 香豆素衍生物在防治脑部重大疾病中的应用
WO2015023691A2 (en) * 2013-08-12 2015-02-19 Benaroya Research Institute At Virginia Mason 4-methylumbelliferone treatment for immune modulation
US20180201640A1 (en) * 2017-01-13 2018-07-19 The Board Of Trustees Of The Leland Stanford Junior University 4-methylumbelliferone derivatives for treatment for immune modulation
US20190269647A1 (en) * 2017-01-13 2019-09-05 The Board Of Trustees Of The Leland Stanford Junior University Methods of treatment using 4-methylumbelliferone and derivatives thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1929839A1 (de) * 1968-06-14 1969-12-18 Dausse Lab 4-tert.-Aminomethyl-7-hydroxycumarine
US6617124B1 (en) * 1998-05-08 2003-09-09 Smithkline Beecham P.L.C. 7-alkoxycoumarins as cytochrome p450 substrates
WO2006102958A1 (en) * 2005-03-29 2006-10-05 Newron Pharmaceuticals S.P.A. Substituted aminoalkyl- and amidoalkyl-benzopyran derivatives
CN103446154A (zh) * 2012-05-29 2013-12-18 中国医学科学院药物研究所 香豆素衍生物在防治脑部重大疾病中的应用
WO2015023691A2 (en) * 2013-08-12 2015-02-19 Benaroya Research Institute At Virginia Mason 4-methylumbelliferone treatment for immune modulation
US20180201640A1 (en) * 2017-01-13 2018-07-19 The Board Of Trustees Of The Leland Stanford Junior University 4-methylumbelliferone derivatives for treatment for immune modulation
US20190269647A1 (en) * 2017-01-13 2019-09-05 The Board Of Trustees Of The Leland Stanford Junior University Methods of treatment using 4-methylumbelliferone and derivatives thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DUNCAN ET AL: "The potential of memory enhancement through modulation of perineuronal nets", BRITISH JOURNAL OF PHARMACOLOGY, vol. 176, no. 18, pages 3611 - 3621, XP071124641, DOI: 10.1111/bph.14672 *
LEONARDO PISANI ET AL: "Discovery of Potent Dual Binding Site Acetylcholinesterase Inhibitors via Homo- and Heterodimerization of Coumarin-Based Moieties", CHEMMEDCHEM, vol. 12, no. 16, pages 1349 - 1358, XP009525371, DOI: 10.1002/cmdc.201700282 *
NERELLA SRIDHAR GOUD ET AL: "Synthesis and biological evaluation of morpholines linked coumarin–triazole hybrids as anticancer agents", CHEMICAL BIOLOGY ﹠DRUG DESIGN, vol. 94, no. 5, 31 August 2019 (2019-08-31), pages 1919 - 1929, XP009525370, DOI: 10.1111/cbdd.13578 *

Also Published As

Publication number Publication date
WO2021078991A1 (en) 2021-04-29
EP4048257A1 (en) 2022-08-31
JP2022554230A (ja) 2022-12-28
US20220380331A1 (en) 2022-12-01

Similar Documents

Publication Publication Date Title
Austin et al. The effects of intrathecal injection of a hyaluronan-based hydrogel on inflammation, scarring and neurobehavioural outcomes in a rat model of severe spinal cord injury associated with arachnoiditis
JP7836583B2 (ja) 視神経疾患治療用組成物、その調製方法およびその使用
DE102007012165A1 (de) Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
EP2931292B1 (en) Compositions and methods comprising polyethylene glycol and magnesium for treatment of neuronal injury
JP6837679B2 (ja) 硫酸デキストランの新しい使用
EP3197445B1 (en) Proline or proline derivatives for the treatment of dementia
Osborn et al. The role of the subfornical organ in angiotensin II–salt hypertension in the rat
Zhang et al. Liraglutide provides neuroprotection by regulating autophagy through the AMPK-FOXO3 signaling pathway in a spinal contusion injury rat model
WO2020165802A1 (en) Compositions and methods relating to use of agonists of alpha5-containing gabaa receptors
US20090263507A1 (en) Biological markers and response to treatment for pain, inflammation, neuronal or vascular injury and methods of use
CN115023222A (zh) 神经系统病症的治疗
Zhang et al. Ultrasound improves the outcomes of cardiopulmonary resuscitation in rats by stimulating the cholinergic anti-inflammatory pathway
Masegosa et al. ICA-27243 improves neuromuscular function and preserves motoneurons in the transgenic SOD1G93A mice
US11992469B2 (en) Targeting mitochondrial dynamics by mitochondrial fusion promoter M1 as a treatment strategy for nervous system injury
TW200922605A (en) Composition and treatment
EP3807295B1 (en) Ligand controling interaction between gags with their effector molecules and use thereof
Wang et al. Electroacupuncture Regulates Synaptic Plasticity of Dentate Gyrus to Improve Spatial Memory Impairment in Diabetes Model Rats
Korimová et al. Protective effects of glucosamine-kynurenic acid after compression-induced spinal cord injury in the rat
US20230346746A1 (en) Eletriptan hydrobromide for treatment of spinal cord injury and improvement of locomotor function
JP7235658B2 (ja) 疼痛治療のためのａｎｇ（１－７）誘導体オリゴペプチド
CN117042773A (zh) Chk2抑制剂的用途
AU2015213386A1 (en) Biological markers and response to treatment for pain, inflammation, neuronal or vascular injury and methods of use
US20080058260A1 (en) Reversible inhibition of pyramidal gap junction activity
CN116407546A (zh) N-乙酰甘露糖胺在制备药物中的应用
EA046226B1 (ru) Применение фармацевтической композиции в качестве лекарственного средства для защиты и/или репарации/восстановления гематоэнцефалического барьера

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20220915

Address after: Liz

Applicant after: University OF LEEDS

Address before: Liz

Applicant before: Quirk John

Applicant before: R. Foster

Applicant before: J. Duncan

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination